Worg Pharma Acquires Apitope's Autoimmune Platform and Pipeline

Worg Pharma of Hangzhou , a clinical-stage allergy company, acquired the platform and therapeutic pipeline of Apitope International of Belgium in an asset purchase. The price was not disclosed. Apitope’s innovative pipeline consists of clinical, preclinical and discovery stage assets to treat autoimmune diseases that have large unmet medical needs. The portfolio includes a first-in-class antigen-specific immunotherapy targeting the immunological basis of autoimmune diseases. More details.... Share this with colleagues: // //